NewsRSSToday
A person with Parkinson's disease shares their personal experience living with the condition and how levodopa medication affects them. They describe having good moments when their body works well and their mind is clear, but these moments don't last. The author emphasizes that everyone's experience with Parkinson's treatment is different, so people should talk to their doctor before making changes to their medications.
WHY IT MATTERSThis first-person account helps other Parkinson's patients understand that fluctuating medication effectiveness and 'on-off' periods are common experiences, validating their own struggles with levodopa management.
Clinical trialRSSToday
A company called Photopharmics has finished testing a light therapy device called Celeste for Parkinson's disease. The last patient in the large study has completed all their visits. This is an important step toward potentially getting the device approved for patients to use.
WHY IT MATTERSCompletion of this pivotal trial means Celeste light therapy could move closer to FDA approval, potentially offering Parkinson's patients a new non-drug treatment option if results are positive.
AdvocacyRSSYesterday
This article discusses an important challenge that families with Parkinson's disease face: deciding when a loved one should stop driving or reduce their independence due to safety concerns. The piece uses the example of noticing a parent swerving while driving to illustrate how difficult these conversations can be. It explores the tension between keeping someone safe and respecting their right to make their own choices.
WHY IT MATTERSParkinson's disease patients and caregivers need guidance on recognizing when symptoms like freezing episodes or motor control problems make activities like driving unsafe, so they can have informed conversations about maintaining safety without unnecessarily restricting independence.
Clinical trialRSSYesterday
A company called Biovie has finished enrolling patients in a study testing a new oral medication called bezisterim for early-stage Parkinson's disease. The medication is being tested as a standalone treatment that patients could take by mouth. The researchers will now analyze all the data collected, with results expected later this year.
WHY IT MATTERSIf bezisterim proves effective in this Phase 2 trial, it could offer Parkinson's patients a new oral treatment option that works alone without requiring combination with other medications.
ResearchRSS2 days ago
Scientists at Texas A&M University found a protective pathway in the brain that could slow Parkinson's disease progression. This pathway involves receptors that respond to nicotine (a chemical in tobacco) but doesn't require actually using tobacco. In mice, increasing these receptors helped prevent Parkinson's symptoms — but only in female mice, not male mice.
WHY IT MATTERSThis sex-specific finding could lead to new Parkinson's treatments tailored differently for women and men, addressing a gap in how the disease progresses differently between sexes.
NewsRSS2 days ago
A family shares their personal story about how their uncle Brandon's Parkinson's disease diagnosis challenged and changed their family's approach to faith and difficult conversations. The article explores how a serious neurological illness forced the family to move beyond surface-level discussions and address deeper emotional and spiritual questions they had previously avoided.
WHY IT MATTERSPersonal stories from families living with Parkinson's disease help newly diagnosed patients and caregivers understand that emotional and spiritual struggles are common, and that open family conversations can be part of the healing process.
PolicyRSS3 days ago
Vermont has become the first state in the US to ban paraquat, a weed-killing chemical that scientists have linked to a higher risk of developing Parkinson's disease. Similar bans are being considered in about a dozen other states, including New York, Pennsylvania, and Minnesota. This action is based on research showing that exposure to paraquat may increase the chances of getting Parkinson's disease.
WHY IT MATTERSIf you have Parkinson's disease or a family history of it, this ban reduces your potential exposure to a chemical that research suggests may trigger or worsen the condition.
NewsRSS4 days ago
A 49-year-old woman with Parkinson's disease is celebrating her birthday and reflecting on living with the condition. She shares that she was diagnosed nine years ago and is grateful to be marking another year of life. The article focuses on her personal perspective about managing life with Parkinson's disease.
WHY IT MATTERSThis personal story from someone living with Parkinson's disease for nine years offers patients and caregivers insight into long-term life management and emotional resilience with a progressive neurological condition.
PipelineRSS4 days ago
A company called Cellular Intelligence has bought the rights to develop a new Parkinson's disease treatment from another company called Novo Nordisk. The treatment uses stem cells (special cells that can become different types of cells) from donors. Cellular Intelligence will use artificial intelligence technology to help develop and manufacture this therapy, and Novo Nordisk is investing money in the company to support this work.
WHY IT MATTERSThis acquisition signals renewed investment in stem cell therapy for Parkinson's disease, potentially accelerating development of a treatment option that could help patients with progressive motor symptoms who have limited disease-modifying therapies available.